Skip to main content
    N

    Nurix Therapeutics Inc (NRIX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $14.73
    -0.75 (-4.84%)

    Market Cap: $1.69B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Nurix Therapeutics Inc (NRIX) Financials: Revenue, Profit and Cash Flow

    Updated Oct 12, 2026. Financial statements from company filings, amounts in US dollars.

    Nurix Therapeutics reported revenue of $83.98M for the fiscal year ended Nov 30, 2025, up 54.0% from the year before. That year, net income was -$264.46M with a net margin of -314.9%, operating cash flow was -$249.47M and free cash flow was -$263.47M. The quarter ended Aug 31, 2026 had revenue of $673.06M and net income of $549.81M.

    Revenue and Margins

    Over the 7 years to Nov 2025, revenue grew from $37.45M, a compound annual rate of 12.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Nov 2025$83.98M+54.0%100.0%-340.2%-314.9%
    Nov 2024$54.55M-29.1%100.0%-390.5%-354.9%
    Nov 2023$76.99M+99.3%100.0%-201.4%-187.0%
    Nov 2022$38.63M+29.8%100.0%-476.0%-466.9%
    Nov 2021$29.75M+66.9%100.0%-396.3%-393.9%
    Nov 2020$17.82M-42.7%100.0%-364.7%-242.7%
    Nov 2019$31.11M-16.9%100.0%-71.5%-69.7%
    Nov 2018$37.45MN/A-8.2%-26.0%-25.2%
    Annual, fiscal years ended Nov 2018 to Nov 2025

    Income Statement

    In the fiscal year ended Nov 2025, the net loss widened from the year before. In the quarter ended Aug 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemNov 2025Nov 2024Nov 2023Nov 2022Nov 2021Nov 2020Nov 2019Nov 2018
    Revenue$83.98M$54.55M$76.99M$38.63M$29.75M$17.82M$31.11M$37.45M
    Cost of revenue$0$0$0$0$0$0$0$40.51M
    Gross profit$83.98M$54.55M$76.99M$38.63M$29.75M$17.82M$31.11M-$3.06M
    Research and development$316.90M$221.63M$189.15M$184.50M$116.43M$66.49M$45.02M$40.51M
    Operating income-$285.67M-$213.03M-$155.06M-$183.87M-$117.89M-$64.98M-$22.24M-$9.74M
    Net income-$264.46M-$193.57M-$143.95M-$180.36M-$117.19M-$43.24M-$21.70M-$9.43M
    EBITDA-$277.13M-$207.89M-$146.83M-$172.63M-$110.10M-$62.53M-$19.99M-$6.75M
    Fiscal years ended Nov 2018 to Nov 2025

    Quarterly

    Line itemAug 2026May 2026Feb 2026Nov 2025Aug 2025May 2025Feb 2025Nov 2024Aug 2024May 2024Feb 2024Nov 2023
    Revenue$673.06M$9.04M$6.25M$13.58M$7.89M$44.06M$18.45M$13.28M$12.59M$12.09M$16.59M$15.16M
    Gross profit$673.06M$9.04M$6.25M$13.58M$7.89M$44.06M$18.45M$13.28M$12.59M$12.09M$16.59M$15.16M
    Operating income$559.45M-$94.20M-$92.50M-$83.09M-$91.39M-$48.32M-$62.86M-$64.66M-$54.61M-$48.54M-$45.22M-$45.33M
    Net income$549.81M-$89.53M-$87.17M-$78.22M-$86.42M-$43.46M-$56.35M-$58.55M-$48.96M-$44.55M-$41.52M-$41.96M
    Last 12 quarters

    Balance Sheet

    As of Nov 2025, cash and equivalents exceeded short-term debt of $2.82M by $244.14M.

    Annual

    Line itemNov 2025Nov 2024Nov 2023Nov 2022Nov 2021Nov 2020Nov 2019Nov 2018
    Total assets$688.13M$669.34M$355.60M$416.76M$476.77M$396.34M$44.05M$45.40M
    Current assets$606.82M$619.39M$295.50M$318.45M$311.12M$298.43M$39.35M$40.65M
    Cash and equivalents$246.96M$110.00M$54.63M$64.47M$80.51M$119.36M$34.82M$25.59M
    Total liabilities$149.39M$142.35M$155.10M$113.06M$134.47M$106.07M$53.57M$34.05M
    Short-term debt$2.82M$8.01M$7.49M$5.53M$3.85M$7.63M$4.62M$2.84M
    Shareholder equity$538.75M$526.99M$200.49M$303.70M$342.30M$290.27M-$57.71M-$36.85M
    Fiscal years ended Nov 2018 to Nov 2025

    Quarterly

    Line itemAug 2026May 2026Feb 2026Nov 2025Aug 2025May 2025Feb 2025Nov 2024Aug 2024May 2024Feb 2024Nov 2023
    Total assets$1.20B$535.54M$636.13M$688.13M$522.47M$591.55M$615.04M$669.34M$513.60M$511.03M$312.67M$355.60M
    Total liabilities$226.99M$132.91M$155.24M$149.39M$150.22M$143.95M$134.13M$142.35M$136.74M$140.34M$143.93M$155.10M
    Cash and equivalents$720.24M$67.69M$71.19M$246.96M$78.44M$84.26M$75.92M$110.00M$99.04M$116.79M$49.81M$54.63M
    Shareholder equity$968.31M$402.63M$480.89M$538.75M$372.25M$447.60M$480.92M$526.99M$376.86M$370.69M$168.75M$200.49M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Nov 2025.

    Annual

    Line itemNov 2025Nov 2024Nov 2023Nov 2022Nov 2021Nov 2020Nov 2019Nov 2018
    Operating cash flow-$249.47M-$172.58M-$81.36M-$159.81M-$84.36M-$80.00K$601.00K-$31.68M
    Capital expenditures$14.00M$9.27M$8.40M$12.24M$5.66M$4.55M$1.65M$1.59M
    Free cash flow-$263.47M-$181.86M-$89.77M-$172.05M-$90.03M-$4.63M-$1.05M-$33.27M
    Investing cash flow$147.85M-$257.71M$68.30M$27.20M-$108.25M-$254.40M$8.50M$39.99M
    Financing cash flow$238.64M$485.67M$3.22M$117.19M$153.88M$339.02M$126.00K$529.00K
    Fiscal years ended Nov 2018 to Nov 2025

    Quarterly

    Line itemAug 2026May 2026Feb 2026Nov 2025Aug 2025May 2025Feb 2025Nov 2024Aug 2024May 2024Feb 2024Nov 2023
    Operating cash flow$615.63M-$96.57M-$71.91M-$67.83M-$57.38M-$63.16M-$61.09M-$48.75M-$42.18M-$39.70M-$41.95M$26.69M
    Capital expenditures$1.39M$1.94M$1.04M$5.13M$2.71M$2.67M$3.48M$2.10M$2.35M$1.94M$2.88M$2.58M
    Free cash flow$614.24M-$98.51M-$72.96M-$72.96M-$60.10M-$65.84M-$64.57M-$50.86M-$44.52M-$41.64M-$44.84M$24.10M
    Last 12 quarters

    Frequently Asked Questions About NRIX

    What is Nurix Therapeutics' annual revenue?

    Nurix Therapeutics reported revenue of $83.98M for the fiscal year ended Nov 30, 2025.

    How fast is Nurix Therapeutics' revenue growing?

    Revenue was up 54.0% for the fiscal year ended Nov 30, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 29.5%.

    Is Nurix Therapeutics profitable?

    No. Nurix Therapeutics reported net income of -$264.46M for the fiscal year ended Nov 30, 2025, with a net margin of -314.9%.

    How much free cash flow does NRIX generate?

    For the fiscal year ended Nov 30, 2025, operating cash flow of -$249.47M minus capital expenditures of $14.00M produced free cash flow of -$263.47M.

    How much debt does Nurix Therapeutics have?

    The balance sheet dated Nov 30, 2025 reported short-term debt of $2.82M and cash and equivalents of $246.96M.